Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study. (2nd April 2016)

• Record Type: Journal Article
• Authors: Dalfrà, Maria Grazia; Soldato, Angela; Moghetti, Paolo; Lombardi, Simonetta; Vinci, Carmela; De Cata, Angela Pia; Romanelli, Tiziana; Bonomo, Matteo; Sciacca, Laura; Tata, Federica; Ragazzi, Eugenio; Filippi, Alessio; Burlina, Silvia; Lapolla, Annunziata
• Is Part Of: Journal of maternal-fetal & neonatal medicine. Volume 29:Number 7(2016)
• Page Start: 1061
• Page End: 1065
• Publication Date: 2016-04-02
• Subjects: Diabetes -- insulin therapy -- pregnancy; Obstetrics -- Periodicals; Perinatology -- Periodicals; Infants (Newborn) -- Diseases -- Periodicals; Neonatology -- Periodicals; 618.2
• DOI: 10.3109/14767058.2015.1033619
• Languages: English
• ISSNs: 1476-7058

Abstract

Abstract: Objective : The aim of this study was to study the efficacy and safety of long-acting insulin analog insulin lispro protamine suspension (ILPS) in diabetic pregnant women. Methods : In a multicenter observational retrospective study, we evaluated pregnancy outcome in 119 women affected by type 1 diabetes and 814 with gestational diabetes (GDM) treated during pregnancy with ILPS, compared with a control group treated with neutral protamine hagedorn (NPH) insulin. Results : Among type 1 diabetic patients, fasting blood glucose at the end of pregnancy was significantly lower in ILPS-treated than in NPH-treated patients. HbA1c levels across pregnancy did not differ between groups. Caesarean section and preterm delivery rates were significantly lower in the ILPS-women. Fetal outcomes were similar in the ILPS and NPH groups. Among GDM women, fasting blood glucose at the end of pregnancy was significantly lower in ILPS-treated than in NPH-treated patients. Duration of gestation was significantly longer, caesarian section and preterm delivery rates were lower in the ILPS-treated group. In addition, there were significantly fewer babies with an excessive ponderal index or neonatal hypoglycemic episodes in the ILPS group than in the NPH group. Conclusions : Association of ILPS with rapid-acting analogs in pregnancy is safe in terms of maternal and fetal outcomes.